Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3114062 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY3114062 (SC) | EXPERIMENTAL | LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg. |
| LY3114062 (IV) | EXPERIMENTAL | LY3114062 given once intravenous (IV). |
| Placebo | PLACEBO_COMPARATOR | Placebo (sodium chloride injection) given as a single SC dose. |
| Name | Type | Description |
|---|---|---|
| LY3114062 SC | DRUG | LY3114062 administered SC. |
| Placebo | DRUG | Placebo administered SC. |
| LY3114062 IV | DRUG | LY3114062 administered IV. |
Inclusion Criteria: * Signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at screening. * Presence of at least 3 out of 66 swollen joints at screening and baseline, as determined by the swollen joint count assessment forms. Exclusion Criteria: * Synthetic disease-mod...
LY3114062 is an investigational small molecule being developed for the treatment of inflammatory arthritis. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LY3114062 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY.
LY3114062 is in Phase 1 clinical development. A Phase 1 safety study has been completed, but the drug remains investigational and has not received regulatory approval.
LY3114062 has one completed Phase 1 trial, NCT02144272, which evaluated its safety in participants with inflammatory arthritis. The study enrolled 41 participants across Bulgaria, Georgia, Moldova, and Romania.
LY3114062 is not FDA approved. It is an investigational drug that has completed a Phase 1 safety study and remains in clinical development.